Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

SELL Ascletis Pharma: Why the COVID-19 Update Does Not Make Sense

Ascletis Pharma: Reiterate Sell, 29% Downside

Ascletis Pharma: Sell the Hype Of (Possible) Coronavirus Clinical Trial

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<p>We initiated trade idea on Ascletis Pharma on the hype surrounding its drug candidates being reported to be used in clinical trial to treat coronavirus on Feb 5th. We have followed up with several notes on the company's continuous effort of making sub-standard announcement with respect to the progress of clinical research. The stock has since fallen by 26% and trades at HKD 2.96/share, which is around our target price. Therefore we would close the trade with 26% profit. </p>

We initiated trade idea on Ascletis Pharma on the hype surrounding its drug candidates being reported to be used in clinical trial to treat coronavirus on Feb 5th. We have followed up with several notes on the company's continuous effort of making sub-standard announcement with respect to the progress of clinical research. The stock has since fallen by 26% and trades at HKD 2.96/share, which is around our target price. Therefore we would close the trade with 26% profit. 

Trade Idea: Close the SHORT on Ascletis Pharma and Pocket 26% Profit

Ascletis Pharma Inc

Trade Idea: Close the SHORT on Ascletis Pharma and Pocket 26% Profit